PL2958888T3 - Związki dwupierścieniowe - Google Patents

Związki dwupierścieniowe

Info

Publication number: PL2958888T3
Authority: PL; Poland
Prior art keywords: bicyclic compounds; bicyclic; compounds
Prior art date: 2013-02-21

Application number

PL14709822T

Other languages

English (en)

Inventor

T. G. Murali Dhar

Hai-Yun Xiao

Alaric J. Dyckman

Eric J. Chan

Marta Dabros

Daniel Richard Roberts

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-02-21

Filing date

2014-02-21

Publication date

2017-07-31

2014-02-21 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2017-07-31 Publication of PL2958888T3 publication Critical patent/PL2958888T3/pl

Links

125000002619 bicyclic group Chemical group 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/50—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/18—Polycyclic aromatic halogenated hydrocarbons
- C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
- C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
- C07C49/67—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having two rings, e.g. tetralones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Epidemiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL14709822T 2013-02-21 2014-02-21 Związki dwupierścieniowe PL2958888T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361767531P	2013-02-21	2013-02-21
EP14709822.2A EP2958888B1 (en)	2013-02-21	2014-02-21	Bicyclic compounds

Publications (1)

Publication Number	Publication Date
PL2958888T3 true PL2958888T3 (pl)	2017-07-31

Family

ID=50272738

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14709822T PL2958888T3 (pl)	2013-02-21	2014-02-21	Związki dwupierścieniowe

Country Status (34)

Country	Link
US (3)	US9115054B2 (pl)
EP (1)	EP2958888B1 (pl)
JP (1)	JP6277210B2 (pl)
KR (1)	KR102242265B1 (pl)
CN (1)	CN105026362B (pl)
AR (1)	AR094851A1 (pl)
AU (1)	AU2014218883B2 (pl)
BR (1)	BR112015019919A2 (pl)
CA (1)	CA2902168C (pl)
CL (1)	CL2015002358A1 (pl)
CY (1)	CY1118641T1 (pl)
DK (1)	DK2958888T3 (pl)
EA (1)	EA025294B1 (pl)
ES (1)	ES2613262T3 (pl)
HR (1)	HRP20170247T1 (pl)
HU (1)	HUE031626T2 (pl)
IL (1)	IL240613B (pl)
LT (1)	LT2958888T (pl)
MA (1)	MA38425B1 (pl)
MX (1)	MX2015010347A (pl)
MY (1)	MY173990A (pl)
PE (1)	PE20151746A1 (pl)
PH (1)	PH12015501793B1 (pl)
PL (1)	PL2958888T3 (pl)
PT (1)	PT2958888T (pl)
RS (1)	RS55703B1 (pl)
SG (1)	SG11201506408TA (pl)
SI (1)	SI2958888T1 (pl)
SM (2)	SMT201700115T1 (pl)
TN (1)	TN2015000356A1 (pl)
TW (1)	TWI613182B (pl)
UY (1)	UY35338A (pl)
WO (1)	WO2014130752A2 (pl)
ZA (1)	ZA201506965B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3022176B8 (en)	2013-07-15	2019-12-25	The Regents of the University of California	Azacyclic constrained analogs of fty720
TWI689487B (zh)	2014-08-20	2020-04-01	美商必治妥美雅史谷比公司	經取代雙環化合物
EP3352753A4 (en) *	2015-09-24	2019-03-13	The Regents of The University of California	SYNTHETIC SPHINGOLIPIDE-SIMILAR MOLECULES, MEDICAMENTS, METHODS FOR THEIR SYNTHESIS AND TREATMENT PROCEDURES
ES2859478T3 (es)	2016-09-02	2021-10-04	Bristol Myers Squibb Co	Compuestos heterocíclicos tricíclicos sustituidos
WO2019032631A1 (en)	2017-08-09	2019-02-14	Bristol-Myers Squibb Company	Oxime ether compounds
US11046646B2 (en)	2017-08-09	2021-06-29	Bristol-Myers Squibb Company	Alkylphenyl compounds
WO2021062168A1 (en) *	2019-09-25	2021-04-01	The Regents Of The University Of California	Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
WO2025083549A1 (en)	2023-10-16	2025-04-24	Sun Pharma Advanced Research Company Limited	Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4200750A (en)	1977-01-07	1980-04-29	Westwood Pharmaceuticals Inc.	4-Substituted imidazo [1,2-a]quinoxalines
US6069143A (en)	1994-12-20	2000-05-30	Smithkline Beecham Corporation	Fibrinogen receptor antagonists
US7479504B2 (en)	2002-01-18	2009-01-20	Merck & Co., Inc.	Edg receptor agonists
ATE448193T1 (de)	2002-01-18	2009-11-15	Merck & Co Inc	ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US20050070506A1 (en)	2002-01-18	2005-03-31	Doherty George A.	Selective s1p1/edg1 receptor agonists
US7309721B2 (en)	2002-03-01	2007-12-18	Merck + Co., Inc.	Aminoalkylphosphonates and related compounds as Edg receptor agonists
JP2005533058A (ja)	2002-06-17	2005-11-04	メルク　エンド　カムパニー　インコーポレーテッド	Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
BRPI0410439A (pt)	2003-05-19	2006-06-06	Irm Llc	compostos e composições imunossupressoras
US7605171B2 (en)	2003-12-17	2009-10-20	Merck & Co., Inc.	(3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
TW200538433A (en)	2004-02-24	2005-12-01	Irm Llc	Immunosuppressant compounds and compositiions
AU2005299851B2 (en)	2004-10-22	2011-03-17	Merck Sharp & Dohme Corp.	2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
AU2006214314B2 (en)	2005-02-14	2012-02-09	University Of Virginia Patent Foundation	Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
CN101193852A (zh)	2005-02-18	2008-06-04	因诺迪亚有限公司	4-羟基异亮氨酸类似物及其用途
EP1858889A1 (en)	2005-03-08	2007-11-28	Biota Scientific Management Pty. Ltd.	Bicyclic nucleosides and nucleotides as therapeutic agents
BRPI0609668A2 (pt)	2005-03-23	2011-10-18	Actelion Pharmaceuticals Ltd	composto, composição farmacêutica, e, uso de um composto
CN101203512A (zh)	2005-04-22	2008-06-18	第一三共株式会社	杂环化合物
BRPI0612028A2 (pt)	2005-06-08	2010-10-13	Novartis Ag	oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
WO2007024922A1 (en)	2005-08-23	2007-03-01	Irm Llc	Immunosuppressant compounds and compositions
US20070203111A1 (en)	2006-01-06	2007-08-30	Sepracor Inc.	Cycloalkylamines as monoamine reuptake inhibitors
KR20080086546A (ko)	2006-01-27	2008-09-25	유니버시티 오브 버지니아 페이턴트 파운데이션	신경병증성 통증의 치료 방법
WO2007088450A2 (en)	2006-02-01	2007-08-09	Pfizer Products Inc.	Chromane antagonist of the h-3 receptor
JP2009530389A (ja)	2006-03-21	2009-08-27	エピックスデラウェア，インコーポレイテッド	Ｓ１ｐ受容体調節化合物及びその使用
US7989472B2 (en)	2006-03-23	2011-08-02	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
MX2008012738A (es)	2006-04-03	2009-02-06	Astellas Pharma Inc	Heterocompuesto.
JP2009269819A (ja)	2006-08-25	2009-11-19	Asahi Kasei Pharma Kk	アミン化合物
ES2400163T3 (es)	2006-09-08	2013-04-08	Actelion Pharmaceuticals Ltd.	Derivados de piridil-3-ilo como agentes de inmunomodulación
CL2007003784A1 (es) *	2006-12-21	2008-06-27	Abbott Lab	Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato
GB0625648D0 (en)	2006-12-21	2007-01-31	Glaxo Group Ltd	Compounds
CN101610674A (zh) *	2006-12-21	2009-12-23	艾博特公司	鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物
US8217027B2 (en)	2006-12-21	2012-07-10	Abbott Laboratories	Sphingosine-1-phosphate receptor agonist and antagonist compounds
EP2114906B1 (en)	2007-02-02	2014-08-06	F. Hoffmann-La Roche AG	2-aminooxazolines as taar1 ligands for cns disorders
PT2125797E (pt)	2007-03-16	2014-03-11	Actelion Pharmaceuticals Ltd	Derivados aminopiridina como agonistas do receptor s1p1/edg1
ES2622423T3 (es)	2007-10-04	2017-07-06	Merck Serono S.A.	Derivados de oxadiazol
RU2010121969A (ru)	2007-11-01	2011-12-10	Актелион Фармасьютиклз Лтд (Ch)	Новые производные пиримидина
GB0725105D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
US8153686B2 (en)	2008-04-01	2012-04-10	Theravance, Inc.	Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
WO2010042998A1 (en)	2008-10-17	2010-04-22	Akaal Pharma Pty Ltd	S1p receptors modulators
WO2010069949A1 (en)	2008-12-18	2010-06-24	Merck Serono S.A.	Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (en)	2008-12-26	2010-06-30	Laboratorios Almirall, S.A.	1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en)	2009-01-19	2010-07-28	Almirall, S.A.	Oxadiazole derivatives as S1P1 receptor agonists
EP2389377B1 (en)	2009-01-23	2014-07-16	Bristol-Myers Squibb Company	Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
ES2405054T3 (es)	2009-01-23	2013-05-30	Bristol-Myers Squibb Company	Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
JP2012515787A (ja)	2009-01-23	2012-07-12	ブリストル−マイヤーズスクイブカンパニー	自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
JP2012517445A (ja)	2009-02-10	2012-08-02	アボット・ラボラトリーズ	Ｓ１ｐ受容体アゴニストおよびアンタゴニストを調製するための方法
US8399451B2 (en)	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
JP5728487B2 (ja)	2009-10-29	2015-06-03	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	三環式ヘテロ環化合物
WO2011133734A1 (en)	2010-04-23	2011-10-27	Bristol-Myers Squibb Company	4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
CN102260178A (zh)	2010-05-25	2011-11-30	中国医学科学院药物研究所	羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
CN102260177A (zh)	2010-05-25	2011-11-30	中国医学科学院药物研究所	丙二醇类衍生物、其制备方法和其药物组合物与用途
JP5788507B2 (ja)	2010-07-20	2015-09-30	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	置換３−フェニル−１，２，４−オキサジアゾール化合物
EP2619190B1 (en)	2010-09-24	2015-08-12	Bristol-Myers Squibb Company	Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012061459A1 (en)	2010-11-03	2012-05-10	Bristol-Myers Squibb Company	Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
US9682078B2 (en) *	2011-03-18	2017-06-20	University Of Virginia Patent Foundation	Compositions and methods for tissue engineering and cell based therapies
EP2541155B1 (en)	2011-04-26	2016-02-24	Panasonic Intellectual Property Management Co., Ltd.	Heating system, and heating system control method
GB201107325D0 (en) *	2011-05-04	2011-06-15	Glaxosmithkline Llc	Novel compounds
EP2706999B1 (en)	2011-05-13	2019-08-28	Celgene International II Sàrl	Selective heterocyclic sphingosine 1 phosphate receptor modulators
EA027809B1 (ru)	2012-07-27	2017-09-29	Биоген Айдек Ма Инк.	Соединения, которые являются s1p-модулирующими агентами и/или atx-модулирующими агентами

2014
- 2014-02-20 TW TW103105719A patent/TWI613182B/zh not_active IP Right Cessation
- 2014-02-20 UY UY0001035338A patent/UY35338A/es unknown
- 2014-02-20 US US14/185,164 patent/US9115054B2/en active Active
- 2014-02-21 SM SM20170115T patent/SMT201700115T1/it unknown
- 2014-02-21 PT PT147098222T patent/PT2958888T/pt unknown
- 2014-02-21 MY MYPI2015702746A patent/MY173990A/en unknown
- 2014-02-21 HR HRP20170247TT patent/HRP20170247T1/hr unknown
- 2014-02-21 BR BR112015019919A patent/BR112015019919A2/pt not_active Application Discontinuation
- 2014-02-21 AR ARP140100554A patent/AR094851A1/es unknown
- 2014-02-21 PE PE2015001795A patent/PE20151746A1/es active IP Right Grant
- 2014-02-21 EP EP14709822.2A patent/EP2958888B1/en active Active
- 2014-02-21 HU HUE14709822A patent/HUE031626T2/en unknown
- 2014-02-21 CA CA2902168A patent/CA2902168C/en not_active Expired - Fee Related
- 2014-02-21 EA EA201591409A patent/EA025294B1/ru not_active IP Right Cessation
- 2014-02-21 RS RS20170188A patent/RS55703B1/sr unknown
- 2014-02-21 MX MX2015010347A patent/MX2015010347A/es unknown
- 2014-02-21 WO PCT/US2014/017534 patent/WO2014130752A2/en not_active Ceased
- 2014-02-21 KR KR1020157025410A patent/KR102242265B1/ko not_active Expired - Fee Related
- 2014-02-21 MA MA38425A patent/MA38425B1/fr unknown
- 2014-02-21 CN CN201480009497.1A patent/CN105026362B/zh not_active Expired - Fee Related
- 2014-02-21 SG SG11201506408TA patent/SG11201506408TA/en unknown
- 2014-02-21 PL PL14709822T patent/PL2958888T3/pl unknown
- 2014-02-21 JP JP2015558976A patent/JP6277210B2/ja not_active Expired - Fee Related
- 2014-02-21 ES ES14709822.2T patent/ES2613262T3/es active Active
- 2014-02-21 DK DK14709822.2T patent/DK2958888T3/en active
- 2014-02-21 SI SI201430106A patent/SI2958888T1/sl unknown
- 2014-02-21 LT LTEP14709822.2T patent/LT2958888T/lt unknown
- 2014-02-21 AU AU2014218883A patent/AU2014218883B2/en not_active Ceased
2015
- 2015-07-14 US US14/798,498 patent/US9359286B2/en active Active
- 2015-08-14 PH PH12015501793A patent/PH12015501793B1/en unknown
- 2015-08-17 IL IL240613A patent/IL240613B/en active IP Right Grant
- 2015-08-18 TN TN2015000356A patent/TN2015000356A1/en unknown
- 2015-08-21 CL CL2015002358A patent/CL2015002358A1/es unknown
- 2015-09-18 ZA ZA2015/06965A patent/ZA201506965B/en unknown
2016
- 2016-05-06 US US15/148,222 patent/US9487481B2/en active Active
2017
- 2017-02-16 CY CY20171100216T patent/CY1118641T1/el unknown
- 2017-02-21 SM SM201700115T patent/SMT201700115B/it unknown

Also Published As

Publication number	Publication date
EA201591409A1 (ru)	2015-12-30
US9115054B2 (en)	2015-08-25
EP2958888B1 (en)	2016-11-23
SI2958888T1 (sl)	2017-01-31
SMT201700115T1 (it)	2017-03-08
PH12015501793A1 (en)	2015-11-09
CN105026362B (zh)	2017-07-14
CY1118641T1 (el)	2017-07-12
IL240613A0 (en)	2015-10-29
LT2958888T (lt)	2017-02-10
KR102242265B1 (ko)	2021-04-19
US20160251309A1 (en)	2016-09-01
AU2014218883B2 (en)	2017-05-11
CL2015002358A1 (es)	2016-02-26
MA38425B1 (fr)	2019-03-29
RS55703B1 (sr)	2017-07-31
MX2015010347A (es)	2015-11-16
MA38425A1 (fr)	2017-12-29
TN2015000356A1 (en)	2017-01-03
CA2902168A1 (en)	2014-08-28
SG11201506408TA (en)	2015-09-29
HUE031626T2 (en)	2017-07-28
JP6277210B2 (ja)	2018-02-07
ZA201506965B (en)	2017-08-30
TWI613182B (zh)	2018-02-01
IL240613B (en)	2018-06-28
TW201444786A (zh)	2014-12-01
US9359286B2 (en)	2016-06-07
US20150315128A1 (en)	2015-11-05
AU2014218883A1 (en)	2015-10-15
PT2958888T (pt)	2017-02-03
SMT201700115B (it)	2017-03-08
KR20150119352A (ko)	2015-10-23
PE20151746A1 (es)	2015-12-02
DK2958888T3 (en)	2017-03-06
ES2613262T3 (es)	2017-05-23
PH12015501793B1 (en)	2015-11-09
WO2014130752A2 (en)	2014-08-28
MY173990A (en)	2020-03-03
CN105026362A (zh)	2015-11-04
CA2902168C (en)	2019-01-08
US20140235591A1 (en)	2014-08-21
WO2014130752A3 (en)	2014-10-23
US9487481B2 (en)	2016-11-08
AR094851A1 (es)	2015-09-02
JP2016513124A (ja)	2016-05-12
HK1218111A1 (en)	2017-02-03
BR112015019919A2 (pt)	2017-07-18
UY35338A (es)	2014-08-29
HRP20170247T1 (hr)	2017-04-07
EP2958888A2 (en)	2015-12-30
EA025294B1 (ru)	2016-12-30

Publication	Publication Date	Title
GB201309085D0 (en)	2013-07-03	Compounds
AP2015008713A0 (en)	2015-09-30	Tetrahydropyrrolothiazine compounds
GB201310542D0 (en)	2013-07-31	Compounds
GB201302927D0 (en)	2013-04-03	Compounds
GB201311951D0 (en)	2013-08-14	Compounds
GB201309508D0 (en)	2013-07-10	Compounds
GB201317619D0 (en)	2013-11-20	Compounds
GB201319363D0 (en)	2013-12-18	Compounds
ZA201506965B (en)	2017-08-30	Bicyclic compounds
GB201320636D0 (en)	2014-01-08	Compounds
GB201311953D0 (en)	2013-08-14	Compounds
AP3850A (en)	2016-09-30	Azetidinyloxyphenylpyrrolidine compounds
GB201312901D0 (en)	2013-09-04	Compounds
EP2948457A4 (en)	2016-09-07	COMPOUNDS
GB201306794D0 (en)	2013-05-29	Compounds
GB201318461D0 (en)	2013-12-04	Compounds
GB201316014D0 (en)	2013-10-23	Compounds
GB201310460D0 (en)	2013-07-24	Compounds
GB201321553D0 (en)	2014-01-22	Compounds
GB201321283D0 (en)	2014-01-15	Compounds
GB201318323D0 (en)	2013-11-27	Compounds
GB201318143D0 (en)	2013-11-27	Compounds
GB201317118D0 (en)	2013-11-06	Compounds
GB201316717D0 (en)	2013-11-06	Compounds
GB201315947D0 (en)	2013-10-23	Compounds